Agenus (NASDAQ:AGEN) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of Agenus (NASDAQ:AGEN) in a report issued on Wednesday morning. The firm issued a hold rating on the biotechnology company’s stock.

A number of other analysts have also commented on the company. HC Wainwright reissued a buy rating and set a $160.00 price objective on shares of Agenus in a report on Thursday, March 14th. B. Riley decreased their price target on Agenus from $120.00 to $100.00 and set a buy rating for the company in a report on Monday, March 18th.

Agenus Stock Up 6.8 %

Shares of NASDAQ:AGEN opened at $5.31 on Wednesday. Agenus has a twelve month low of $4.78 and a twelve month high of $42.60. The stock’s 50 day moving average is $11.67 and its 200-day moving average is $14.18. The firm has a market capitalization of $111.22 million, a price-to-earnings ratio of -0.37 and a beta of 1.26.

Agenus (NASDAQ:AGEN) last released its quarterly earnings data on Thursday, March 14th. The biotechnology company reported ($2.60) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($2.20). The business had revenue of $83.80 million for the quarter, compared to analysts’ expectations of $54.21 million. Equities research analysts anticipate that Agenus will post -8.21 earnings per share for the current fiscal year.

Insider Activity

In other Agenus news, insider Garo H. Armen acquired 25,000 shares of the business’s stock in a transaction on Thursday, February 15th. The shares were acquired at an average price of $13.00 per share, with a total value of $325,000.00. Following the completion of the transaction, the insider now owns 31,298 shares in the company, valued at $406,874. The acquisition was disclosed in a legal filing with the SEC, which is available at the SEC website. 4.80% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AGEN. U.S. Capital Wealth Advisors LLC purchased a new stake in shares of Agenus during the 1st quarter worth approximately $25,000. Commonwealth Equity Services LLC purchased a new stake in Agenus in the third quarter worth $26,000. Creative Planning purchased a new stake in Agenus in the fourth quarter worth $40,000. American Century Companies Inc. bought a new stake in shares of Agenus in the fourth quarter valued at $41,000. Finally, Sei Investments Co. purchased a new position in shares of Agenus during the 1st quarter valued at $28,000. 61.46% of the stock is currently owned by hedge funds and other institutional investors.

About Agenus

Agenus Inc, a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.